CN108697679B - Amino acid-containing composition - Google Patents
Amino acid-containing composition Download PDFInfo
- Publication number
- CN108697679B CN108697679B CN201780011660.1A CN201780011660A CN108697679B CN 108697679 B CN108697679 B CN 108697679B CN 201780011660 A CN201780011660 A CN 201780011660A CN 108697679 B CN108697679 B CN 108697679B
- Authority
- CN
- China
- Prior art keywords
- fatigue
- amino acid
- exercise
- lipid metabolism
- valine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
Abstract
The present invention addresses the problem of providing an amino acid-containing composition that exhibits a high anti-fatigue effect and/or an effect of enhancing lipid metabolism that is not inferior to conventional compositions, with a small number of amino acid species. The present invention provides an amino acid composition for anti-fatigue and/or lipid hypermetabolism, which is composed of arginine, valine and serine. By providing the anti-fatigue and lipid metabolism-enhancing amino acid composition, fatigue during exercise can be prevented and reduced, and the anti-fatigue and lipid metabolism-enhancing effect is obtained.
Description
Technical Field
The present invention relates to an amino acid-containing composition for anti-fatigue use and/or lipid metabolism enhancement.
Background
Fatigue accompanying exercise is a phenomenon that anyone has experienced, and an increase in fatigue causes a decrease in motivation for exercise and/or a decrease in exercise efficiency. In particular, obese persons and/or patients with metabolic syndrome (including the potential population) are also fatigued to a higher degree than healthy persons, and a decrease in motivation for exercise and/or a decrease in exercise efficiency is marked. Therefore, moderate exercise is effective for the prevention and/or improvement of obesity and/or metabolic syndrome.
On the other hand, with the westernization of dietary life and lifestyle in japan, the number of obese people increased, and in the national health and nutrition survey in 2013, 28.6% for men and 20% for women were obtained. In addition, about half of obese people suffer from metabolic syndromes such as hyperlipidemia and hyperglycemia. In addition, the metabolic syndrome potential population highly suspected of being the metabolic syndrome is up to 51.6% in men and 17.5% in women. That is, for the purpose of extending the health life and controlling medical costs, exercise-based energy expenditure and food ingredient-based body regulation functions have been attracting attention as prevention and improvement of these diseases.
As a conventional food focusing on fatigue associated with exercise, a fatigue recovery peptide obtained by enzymatically decomposing a protein material has been disclosed. Patent document 1 describes a fatigue recovery or tonic agent containing a protein-decomposing peptide, which is obtained by decomposing a protein-containing material with thiol protease derived from germinated soybeans and serine protease derived from microorganisms. Patent document 2 describes an amino acid nutritional composition having a rapid recovery effect of human muscle fatigue, which contains arginine, isoleucine, leucine, valine, lysine, methionine, threonine, histidine, proline, phenylalanine, tryptophan, and glutamine. Patent document 3 describes an amino acid composition for a fatigue preventive agent, which is composed of 6 to 12 kinds of amino acids among proline, alanine, lysine, tryptophan, histidine, threonine, tyrosine, arginine, valine, leucine, and isoleucine. Patent document 4 describes an amino acid composition having an anti-obesity effect based on lipid hypermetabolism while preventing, reducing and recovering fatigue, which is composed of proline, alanine, glycine, valine, threonine, leucine, histidine, serine, lysine, isoleucine, glutamic acid, arginine, methionine, and l-carnitine, and coenzyme Q10 (hereinafter referred to as CoQ 10). In addition, patent document 5 describes a lipid metabolism-promoting agent containing arginine, phenylalanine, and alanine.
The techniques described in these documents have been put to practical use and some of them have achieved certain results, but all of them have problems in the process of using a predetermined protease, problems in the complexity of production management, productivity, economy and the like due to the use of a plurality of amino acids, and also have problems in that the obtained anti-fatigue effect and lipid metabolism-enhancing effect are not necessarily satisfactory as compared with these problems.
Documents of the prior art
Patent document
Patent document 1 Japanese patent laid-open No. 2005-239579
Patent document 2 Japanese patent laid-open No. Hei 08-198748
Summary of the invention
Technical problem to be solved by the invention
Accordingly, an object of the present invention is to provide an amino acid-containing composition having a high anti-fatigue effect and/or an effect of enhancing lipid metabolism, economically and rationally, by eliminating the problems of the prior art as much as possible.
Technical scheme for solving technical problem
In the course of earnest studies by the present inventors to solve the above problems, the present inventors have focused on the amino acids of mosque, valine and serine, found that an amino acid-containing composition containing only these 3 amino acids has a high anti-fatigue effect and/or a high lipid metabolism effect, and completed the present invention after further studies.
That is, the present invention includes the following.
[1] An anti-fatigue amino acid-containing composition comprises amino acids as effective components, wherein the amino acids are arginine, valine and serine.
[2] The amino acid-containing composition for anti-fatigue according to [1], which further comprises a non-amino acid component as an active ingredient.
[3] The amino acid-containing composition for anti-fatigue according to the above [1] or [2], which further comprises an amino acid as an inactive ingredient.
[4] The anti-fatigue amino acid-containing composition according to any one of the above [1] to [3],
50-70 wt% of arginine,
25 to 50% by weight of valine,
serine is 0.1 to 15 wt%.
[5] An anti-fatigue agent comprising the anti-fatigue amino acid-containing composition according to any one of the above [1] to [4 ].
[6] An anti-fatigue food or drink comprising the anti-fatigue amino acid-containing composition according to any one of the above [1] to [4 ].
[7] A packaged anti-fatigue food or drink comprising the anti-fatigue amino acid-containing composition according to any one of the above [1] to [4 ].
[8] An anti-fatigue and lipid metabolism-enhancing amino acid-containing composition comprising an amino acid as an active ingredient, wherein the amino acid is arginine, valine or serine.
[9] The amino acid-containing composition for relieving fatigue and enhancing lipid metabolism according to [8], which further comprises a non-amino acid component as an active ingredient.
[10] The amino acid-containing composition for anti-fatigue and lipid hypermetabolism according to [8] or [9], which further comprises an amino acid as an inactive ingredient.
[11] The amino acid-containing composition for anti-fatigue and lipid metabolism improvement according to any one of the above [8] to [10], wherein,
50-70 wt% of arginine,
25 to 50% by weight of valine,
serine is 0.1 to 15 wt%.
[12] An anti-fatigue and lipid metabolism-promoting agent comprising the amino acid-containing composition for anti-fatigue and lipid metabolism-promoting according to any one of [8] to [11 ].
[13] A food or beverage for relieving fatigue and enhancing lipid metabolism, comprising the amino acid-containing composition for relieving fatigue according to any one of the above-mentioned [8] to [11 ].
[14] A packaged food or drink for anti-fatigue use and lipid hypermetabolism comprising the anti-fatigue amino acid-containing composition according to any one of the above [8] to [11 ].
[15] The anti-fatigue agent according to [5], the anti-fatigue food or drink according to [6], the packaged anti-fatigue food or drink according to [7], the anti-fatigue and lipid metabolism-promoting agent according to [12], the anti-fatigue and lipid metabolism-promoting food or drink according to [13], or the packaged anti-fatigue and lipid metabolism-promoting food or drink according to [14], wherein arginine, valine, and serine are mixed.
[16] Use of arginine, valine, and serine in the production of the amino acid-containing composition according to any one of the above [1] to [4] or [8] to [11], the anti-fatigue agent according to the above [5], the anti-fatigue food or drink according to the above [6], the packaged anti-fatigue food or drink according to the above [7], the anti-fatigue and lipid metabolism-enhancing agent according to the above [12], the anti-fatigue and lipid metabolism-enhancing food or drink according to the above [13], and the packaged anti-fatigue and lipid metabolism-enhancing food or drink according to the above [14 ].
The present invention may be in the form described below.
[1] An anti-fatigue amino acid composition contains arginine, valine and serine.
[2] An amino acid composition for relieving fatigue and promoting lipid metabolism contains arginine, valine and serine.
[3] The amino acid composition according to the above [1] or [2], wherein the arginine is contained in an amount of 50 to 70 wt%.
[4] The amino acid composition according to the above [1] or [2], wherein the valine is contained in an amount of 25 to 50% by weight.
[5] The amino acid composition according to the above [1] or [2], wherein the serine is contained in an amount of 0.1 to 15% by weight.
[6] The amino acid composition according to the above [1] or [2], which contains 50 to 70 wt% of arginine, 25 to 50 wt% of valine, and 0.1 to 15 wt% of serine.
[7] A food or beverage comprising the amino acid composition according to any one of the above [1] to [6 ].
[8] A packaged food or beverage comprising the amino acid composition according to any one of the above [1] to [6 ].
[9] Use of arginine, valine, and serine in the production of the amino acid composition according to any one of the above [1] to [6 ].
[10] A method for preventing or suppressing fatigue, wherein the amino acid composition according to any one of the above [1] to [6] is ingested before and/or after exercise.
[11] A method for preventing or suppressing fatigue and enhancing lipid metabolism, wherein the amino acid composition according to any one of the above [1] to [6] is ingested before and/or after exercise.
ADVANTAGEOUS EFFECTS OF INVENTION
According to the present invention, an amino acid-containing composition which exhibits a higher anti-fatigue effect with a smaller number of amino acid species and has an effect of enhancing lipid metabolism is unexpectedly obtained, and it is expected that an amino acid-containing composition, a food or drink, and the like can be provided more economically and rationally.
Brief description of the drawings
FIG. 1 is a graph showing the amount of change in the blood cortisol concentration measured in example 4.
Modes for carrying out the invention
The present invention is an amino acid-containing composition for anti-fatigue and/or lipid hypermetabolism, which comprises an amino acid as an active ingredient, wherein the amino acid is (1) arginine, (2) valine, or (3) serine.
The preferred content of the amino acids (1) to (3) in the amino acid-containing composition of the present invention is as follows. The content is represented by the content of the amino acids (1) to (3) relative to the total weight.
(1) The content of arginine in the present invention is preferably 50 to 70% by weight based on the total weight of amino acids arginine, valine and serine. It is preferable that the content of arginine is 50% by weight or more because the anti-fatigue effect and/or the lipid metabolism-promoting effect of the present invention are exhibited. Further, if the content of arginine is 70% by weight or less, the anti-fatigue effect and/or lipid metabolism-promoting effect derived from valine and serine other than arginine are further exerted, and therefore, it is preferable.
(2) The content of valine in the present invention is preferably 25 to 50% by weight based on the total weight of arginine, valine and serine. It is preferable that the content of valine is 25% by weight or more because the anti-fatigue effect and/or the lipid metabolism-promoting effect of the present invention are exhibited. Further, if the content of valine is 50% by weight or less, the anti-fatigue effect and/or lipid metabolism-promoting effect derived from arginine and serine other than valine are further exerted, and therefore, it is preferable.
(3) The content of serine in the present invention is preferably 0.1 to 15% by weight based on the total weight of arginine, valine and serine. It is preferable that the content of serine is 0.1% by weight or more because the anti-fatigue effect and/or the lipid metabolism-promoting effect of the present invention are exhibited. Further, if the content of serine is 15% by weight or less, the anti-fatigue effect and/or lipid metabolism-promoting effect derived from arginine and valine other than serine is further exerted, and therefore, it is preferable.
The preferred content of the amino acids (1) to (3) in the amino acid-containing composition of the present invention is as follows. The content is represented by the content of the amino acids (1) to (3) relative to the total weight.
Preferably, (1) arginine is contained in an amount of 50 to 70 wt%, (2) valine is contained in an amount of 25 to 50 wt%, and (3) serine is contained in an amount of 0.1 to 15 wt%. When the content of each amino acid is within the above range, the anti-fatigue effect and/or the lipid metabolism-accelerating effect are remarkably exhibited. Wherein the total content is 100 wt%.
In the present invention, "fatigue" refers to a state in which a sense of fatigue, a sense of lassitude, a muscle pain, a muscle tension, and/or a decrease in exercise efficiency occurs due to the load of exercise. Thus, "anti-fatigue" means preventing or inhibiting a feeling of fatigue, a feeling of burnout, a muscle pain, a tension of a muscle, or the like, and/or a decrease in exercise efficiency. In the present invention, the anti-fatigue effect can be evaluated by measuring a blood biomarker during exercise. As the blood marker, for example, blood glucose level, corticosterone, cortisol, lactic acid, ammonia, creatine kinase, lactate dehydrogenase, etc., TGF-. beta.and the like can be used.
The evaluation based on the measurement of the blood biomarkers can be performed, for example, as follows: the blood concentration of the biomarker in the blood of each of the 2 groups (administration of the amino acid-containing composition) and non-administration groups (no administration or administration of water) was measured and evaluated by applying an exercise load to the group by forced swimming or running machine or by administering adrenaline or the like to bring the group into a simulated exercise state, collecting blood after a certain period of time, and comparing the measured concentrations.
Since the blood glucose level is decreased by the consumption of saccharides due to continuous exercise and the exercise efficiency is also decreased, the decrease in blood glucose level in the administered group (administration of the amino acid-containing composition) is more suppressed than in the non-administered group (no administration or administration of water), and the anti-fatigue effect is more exhibited, and thus the evaluation can be made. On the other hand, corticosterone, cortisol, lactic acid, ammonia, creatine kinase, lactate dehydrogenase, and TGF- β are increased by exercise and the exercise efficiency is decreased, so that the increase in each concentration of the administered group (composition containing amino acids administered) has an anti-fatigue effect as compared with the non-administered group (no administration or water administration), and thus, it can be evaluated.
In addition, in the present invention, the anti-fatigue effect can be evaluated by measuring spontaneous motility. Evaluation based on the spontaneous exercise amount test can be performed, for example, as follows: the evaluation was carried out by applying an exercise load such as forced swimming or running machine to 2 groups of the administration group (administration of the amino acid-containing composition) and the non-administration group (no administration or water administration) for a certain period of time, measuring the spontaneous exercise amount by the spontaneous exercise amount measuring device after the end of the exercise, and comparing the results. The spontaneous exercise amount can be used as an index of the state in which the exercise efficiency is decreased by the exercise load, and the more spontaneous exercise amount in the administered group is compared with that in the non-administered group, the more the anti-fatigue effect is exhibited, and the evaluation can be made therefrom.
The anti-fatigue effect in the present invention can be evaluated by VAS (Visual Analog Scale). The VAS-based evaluation can be performed, for example, as follows: these results were compared and evaluated by giving exercise load for a certain period of time to 2 groups of the administration group (administration of the amino acid-containing composition) and the non-administration group (no administration or administration of water), and then applying VAS for "fatigue feeling" or the like after completion of exercise. VAS can be evaluated subjectively with respect to fatigue, and the lower the "fatigue feeling" or the like of the administered group as compared with the non-administered group, the more the anti-fatigue effect is exhibited.
In the present invention, "lipid hypermetabolism" refers to a state in which neutral fat is decomposed into fatty acid and glycerin, and combustion of fatty acid is activated. Specifically, the state refers to a state in which substances related to the decomposition of neutral fat, such as epinephrine, adenylate cyclase, cyclic AMP, protein kinase a, and hormone-sensitive lipase, substances related to β -oxidation, such as acyl-CoA synthetase and acyl-CoA dehydrogenase, or substances related to the citric acid cycle and the mitochondrial electron transport chain are activated. In the present invention, the lipid metabolism-accelerating effect can be evaluated by measuring a blood biomarker during exercise. Blood biomarkers can be reviewed by measuring, for example, glycerol, free fatty acids (NEFA) in blood, ketone bodies in blood, and the like. The lipid metabolism-enhancing effect can be performed, for example, as follows: the blood concentration of the biomarkers in the blood of the group 2 was measured and evaluated by comparing the measured concentrations by applying an exercise load to the group 2 (the group containing amino acid was administered) and the group 2 (the group was not administered or water was not administered) by forced swimming, treadmill, or the like, or by administering adrenaline or the like to place the group in a simulated exercise state, and collecting the blood after a certain period of time. For example, in the case of blood glycerol concentration, if the values of the area under the curve (AUC) and the maximum blood concentration (Cmax) of glycerol in the administered group are higher than those in the non-administered group, the effect of enhancing fat metabolism is exhibited, and thus the evaluation can be made. Similarly, when NEFA or ketone bodies in blood are present, the blood NEFA or ketone body concentration in blood in the administered group is higher than that in the non-administered group, and the effect of enhancing fat metabolism is exhibited, and thus it can be evaluated.
In one form of the present invention, the amino acid-containing composition of the present invention may further comprise a non-amino acid component having an anti-fatigue and/or lipid metabolism-enhancing effect as an active ingredient. The non-amino acid component as the active ingredient is not particularly limited as long as it has an anti-fatigue and/or lipid metabolism promoting effect, and is a component usually incorporated into pharmaceuticals and/or foods and drinks, for example, vitamins such as vitamin B1, vitamin B2, vitamin B6, and pantothenic acid, vitamin-like substances such as CoQ10, carnitine, and α -lipoic acid, minerals such as iron and zinc, saccharides such as glucose, fructose, galactose, mannose, sucrose, maltose, and lactose, organic acids such as citric acid, tartaric acid, ascorbic acid, malic acid, acetic acid, oxalic acid, phosphoric acid, lactic acid, butyric acid, succinic acid, fumaric acid, and gluconic acid, and polyphenols such as caffeine, theobromine, theanine, and catechin.
In one form of the present invention, the amino acid-containing composition of the present invention is formed from arginine, valine and serine as the effective ingredients of amino acids. In one embodiment of the present invention, the amino acid-containing composition of the present invention may contain, as an ingredient other than the active ingredient, a non-active ingredient in a form that does not act as an active ingredient, for example, in a small amount, even if it is known for anti-fatigue use and/or lipid metabolism-enhancing effect. The non-active ingredient is not particularly limited as long as it can be ingested (administered) into the body, and components usually incorporated into pharmaceutical products and/or foods and drinks, for example, amino acid components such as sodium glutamate and taurine, sweeteners such as sucralose, neotame, acesulfame potassium, sweet protein, stevia extract, licorice extract, momordica grosvenori extract, saccharin sodium, glycyrrhizin, disodium glycyrrhizinate, trisodium glycyrrhizinate, dihydrochalcone, stevioside, and rebaudioside a, minerals such as zinc, selenium, iron, and copper, saccharides such as trehalose, oligosaccharides, and rare sugars, useful microorganisms such as lactic acid bacteria, brefelia, and propionibacterium, or cultures thereof, existing functional raw materials such as royal jelly, collagen, ceramide, glucosamine, astaxanthin, and polyphenol, flavors, pH adjusters, excipients, and acidulants such as citric acid can be incorporated, colorants, emulsifiers, preservatives, and the like.
(1) The amino acids in (1) to (3) and the amino acids which may be contained as non-effective components may be any of L-form, D-form and DL-form, preferably L-form and DL-form, more preferably L-form.
(1) The amino acids described in (1) to (3) and the amino acids that can be contained as non-effective components are not limited to free forms, and amino acid salts may be used. The amino acid salt is not particularly limited as long as it is an amino acid salt which is acceptable as a pharmaceutical and/or food product of the amino acids (1) to (3) and an amino acid which may be contained as another component, and examples thereof include an acid salt of an amino acid and a salt with a base.
Examples of the acid which can form a food acceptable salt of the amino acids (1) to (3) and the amino acids which may be contained as inactive ingredients include inorganic acids such as hydrochloric acid, hydrogen bromide, sulfuric acid and phosphoric acid, and organic acids such as acetic acid, lactic acid, citric acid, tartaric acid, maleic acid, fumaric acid and monomethylsulfuric acid.
Examples of the base to form a food acceptable salt of the amino acids (1) to (3) and the amino acid which may be contained as a non-active ingredient include inorganic bases such as sodium, potassium, calcium, and ammonia, and organic bases such as ethylenediamine, propylenediamine, ethanolamine, monoalkylethanolamine, dialkylethanolamine, diethanolamine, and triethanolamine.
(1) The salt of the amino acid of (1) to (3) and the amino acid which may be contained as an inactive ingredient may be a hydrate (hydrous salt), and examples of the hydrate include mono-to hexahydrate.
(1) The amino acids described in (1) to (3) and the amino acids that can be contained as non-effective components may be any of amino acids extracted and purified from animals, plants, and microorganisms containing these amino acids, and amino acids obtained by chemical synthesis, fermentation, and gene recombination. Further, commercially available amino acids and amino acids that may be contained as non-effective components in the amino acids (1) to (3) may be used.
Each of the amino acids used in the present invention is preferably a high-purity single product. For example, amino acids having a purity higher than that specified in "dietary supplement official manual" are used. In addition, physiologically acceptable salts of these amino acids can also be used.
The amino acid-containing composition of the present invention may be prepared by mixing the above amino acids. In addition, when a solution is prepared, it may be dissolved by mixing with distilled water, ethanol, or the like.
The form of ingestion (administration) of the amino acid-containing composition of the present invention is not limited as long as it can be ingested (administered) into the body, and it is preferably oral administration using, for example, tablets, coated tablets, capsules, granules, powders, solutions, syrups, emulsions, and the like. These various preparations can be formulated by a conventional method using known auxiliaries which are generally used in the field of pharmaceutical preparation technology, such as excipients, binders, disintegrants, lubricants, colorants, flavoring agents, solubilizing agents, suspending agents, and coating agents, for the amino acid-containing composition of the present invention.
In one embodiment of the present invention, the food or drink for fatigue resistance and/or lipid hypermetabolism may be provided as a food or drink (including health functional foods such as specific health foods, functional foods, and nutritional functional foods, nutritional supplementary foods, other health foods, and nutritional supplements) in addition to, for example, a raw material for a food or drink, a food additive, and the like.
The food or beverage for fatigue resistance and/or lipid metabolism improvement of the present invention may be, for example, a dairy product such as a beverage or yogurt, a frozen product, an ice cream, a frozen snack, a cookie, a jelly-like product, a powdered product, a granular product, a sheet-like product, a capsule-like product, a tablet-like product, a solid processed food such as a snack or the like.
In the present invention, the food or drink is a product other than the pharmaceutical composition, and is not particularly limited as long as it is in a form that can be orally ingested, such as a solution, a suspension, an emulsion, a powder, a solid molded product, and the like. Specifically, examples thereof include dairy products such as milk beverages, yogurt beverages, lactic acid bacteria beverages, fermented milks, ice creams, milks and cheeses, refreshing beverages, fruit juice beverages, vegetable beverages, soy milk beverages, coffee beverages, tea beverages, frozen beverages, powdered beverages such as cocoa and smoothie, powdered sports beverages, powdered beverages with enhanced nutrition, powdered foods, powdered soups, steamed wheaten food premixes, concentrated beverages, alcoholic beverages, powdered products such as bread, pasta, noodles, cake premixes, fried meat powders and bread powders, confectionery such as chocolate, chewing gum, candy, cookies, soft candy, snacks, snack foods and desserts, confectionery such as jelly, pudding, seasonings such as processed seasoning, flavored seasoning and cooked premixes, cooked bagged foods such as curry, pasta sauce, thick soup, stew, and soft food, processed fats and oils, and fats, and oils, and fats, and oils, fats, and fats, and oils, fats, and oils, and fats, and oils, and fats, and fats, and fats, and oils, and fats, and oils, fats, and oils, and fats, and fats, and oils, and fats, and oils, and fats, and oils, and fats, Fats and oils such as butter, margarine, spread cream and mayonnaise, instant foods such as freeze-dried foods, agricultural processed products such as canned agricultural products, jam/orange peel jam, boiled beans, cereal flakes and stewed porridge, processed products of aquatic products, processed products of livestock products, frozen foods such as pizza, western-style fried rice, baked vegetables with milk, side food and fried foods, liquid foods, pasty food preparations, and animal feeds and granules.
When used as a food or drink, other components are not particularly limited, and water, proteins, saccharides, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors, and the like can be used as the components in the food or drink. Examples of the protein include whole milk powder, skim milk powder, partially skim milk powder, casein, whey protein concentrate, whey protein isolate, animal and plant proteins such as α -casein, β -casein, κ -casein, β -lactalbumin, α -lactalbumin, lactoferrin, soy protein, egg protein, and meat protein, hydrolysates thereof, and various milk-derived components such as butter, whey minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipids, and lactose. Examples thereof include saccharides, processed starches (dextrin and soluble starches, British starch (British starch), oxidized starches, starch esters, starch ethers, etc.), dietary fibers, etc. Examples of the lipid include animal fats and oils such as lard oil and fish oil, refined oils thereof, hydrogenated oils and transesterified oils, and plant fats and oils such as palm oil, sunflower oil, corn oil, rapeseed oil and coconut oil, refined oils thereof, hydrogenated oils and transesterified oils. Examples of the vitamins include vitamin A, carotenes, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, vitamin PP, nicotinic acid, pantothenic acid, biotin, inositol, choline, and folic acid. Examples of the minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, and selenium. Examples of the organic acid include malic acid, citric acid, lactic acid, and tartaric acid. These ingredients may be used in combination of 2 or more, and synthetic products and/or foods containing a large amount of these ingredients may be used.
In one aspect of the present invention, the food or beverage for fatigue resistance and/or lipid metabolism acceleration is packaged in a container, and the mouth of the container is selected from plastic, paper, metal, ceramic, or a composite material thereof. The container can be filled with the above-mentioned containers. That is, a packaged food or a packaged pharmaceutical product containing the amino acid-containing composition of the present invention can be exemplified. Further, a container may be covered with a shrink film or a light-shielding film (e.g., a metal foil film, a black or dark ink-coated film) made of plastic, and the container and the film may be used in combination of 2 or more. From the viewpoint of deterioration and decomposition (reduction) of flavor due to light transmission and oxygen permeation, the amino acid-containing composition is preferably a combination of a container and a film having light-shielding properties.
According to one embodiment of the present invention, for example, the amino acid-containing composition of the present invention, the anti-fatigue and/or lipid metabolism-enhancing agent, the anti-fatigue and/or lipid metabolism-enhancing food or beverage or the anti-fatigue and lipid metabolism-enhancing packaged food is formed in a unit package form for each meal, wherein arginine, valine and serine are contained in the unit package form, and the amount of the taken one meal is preferably 0.1 to 50g, more preferably 0.5 to 20g, in terms of the total amount of the amino acids, from the viewpoint of the anti-fatigue and/or lipid metabolism-enhancing effect, and more preferably 1 to 10g, further preferably 1 to 8g, further preferably 1 to 6g, further preferably 1 to 5g, from the viewpoint of easy intake without causing a burden even before or during exercise. Here, the "unit package form per meal" means a form in which the intake amount per meal is determined in advance, and for example, a form in which a specific amount of food or drink can be orally taken, not only general food, but also beverage (drink or the like), health supplement food, health functional food, nutritional supplement food, and the like. As the "unit package form per meal", for example, in the case of a liquid beverage, jelly in the form of a gel, paste, or paste, a powdery, granular, capsule-like, or block-like solid food, a form in which a specific amount (dose) can be specified by a package container such as a metal can, a glass bottle (bottle or the like), a plastic container (plastic bottle or the like), a packaging bag, a pouch, a film container, or a carton, or a form in which a specific amount (dose) can be specified by labeling a package container or a homepage with an intake amount (usage, dose) per meal may be mentioned.
The single intake amount per 1 day of the amino acid-containing composition, the anti-fatigue and/or lipid metabolism enhancing agent, the anti-fatigue and/or lipid metabolism enhancing food or beverage or the anti-fatigue and lipid metabolism enhancing container-packaged food or beverage of the present invention is independently determined based on exercise, age, sex, body weight, dietary conditions, and the like, and is, for example, 0.1 to 50g, preferably 0.5 to 25g, more preferably 1 to 10g, based on the total amount of arginine, valine and serine, and further more preferably 1 to 8g, further preferably 1 to 6g, further more preferably 1 to 5g, based on the total amount of arginine, valine and serine, from the viewpoint of further exerting the effect. Preferably, the amount is taken before or during exercise.
The amino acid-containing composition, the anti-fatigue and/or lipid metabolism-promoting agent, the anti-fatigue and/or lipid metabolism-promoting food or beverage for preventing or improving fatigue or a container-packaged food for preventing fatigue or enhancing lipid metabolism of the present invention can be expected to improve exercise efficiency, and therefore, the composition is preferably used for people without exercise habits, exercise enthusiasts, athletes, people with potential obesity, obese people, patients or animals with metabolic syndrome, animals for racing use, and the like.
According to one embodiment of the present invention, the amino acid-containing composition, the anti-fatigue and/or lipid metabolism-promoting agent, the anti-fatigue and/or lipid metabolism-enhancing food or drink or the anti-fatigue and lipid metabolism-enhancing packaged food or drink of the present invention may be in a form with a label effective in anti-fatigue, lipid metabolism-enhancing and improvement of exercise efficiency, and preferably, the prevention of fatigue, improvement of fatigue, reduction of fatigue, alleviation of fatigue, enhancement of lipid metabolism, decomposition of fat, improvement of lipid metabolism and improvement of exercise efficiency are expected, so that the food or drink may have, for example, an effect of improving physical performance, endurance, feeling of relaxing the body, maintaining attention, reducing fatigue of the body, suppressing fatigue feeling, enabling good training, enabling exercise, realizing desirable performance, and the like, The effective annotation is represented by light movement, exceeding the limit of normal performance, and the like. The label of the present invention is not particularly limited as long as it is a label attached to the composition containing an amino acid for fatigue resistance or the composition containing an amino acid for lipid metabolism acceleration, and may be in the form of, for example, a label, an advertisement, or the like, which is effective for attaching a composition to a container, a packaging material, or a text attached thereto, containing an amino acid for fatigue resistance or an amino acid for lipid metabolism acceleration. Note that the label of the present invention may be in the form of a label or advertisement that is effective for adding a composition to a storage medium such as a leaflet, brochure, poster, catalog, poster, book, DVD, etc., an advertisement on an electronic bulletin board, network, etc., or the like. In addition, content equivalent to the annotations of the present invention may be delivered to third parties for negotiation and/or promotion purposes through oral and/or self-recorded, video-on storage media playback.
In the production of the anti-fatigue and/or lipid metabolism-promoting agent, the anti-fatigue and/or lipid metabolism-promoting food or beverage, or the anti-fatigue and lipid metabolism-promoting packaged food or beverage of the present invention, the above amino acids may be used and mixed. In addition, when the beverage is prepared, they may be dissolved by mixing them with distilled water or the like.
Examples
The present invention will be described more specifically below with reference to examples and experimental examples, but the scope of the present invention is not limited to the description of these examples and experimental examples.
[ Experimental example 1]
Measurement of blood glucose level and plasma Cortone concentration (animal test)
30 SD male rats of 6 weeks old were purchased from Japan Keleiya, and domesticated and raised for 1 week. Rats were fasted within 18 hours from the evening of the day before the experiment. However, water is freely ingested. On the day of the test, the test substances (water was orally administered, the present product (obtained by diluting 10 times with water an amino acid-containing composition comprising 18:11: 1L-arginine: L-valine: L-serine in terms of weight ratio), the conventional product (obtained by diluting 10 times with water the granule containing amino acid, carnitine, and CoQ10 shown in Table 1) were orally administered to rats, and the present product (amino acid-containing granule containing 1g/kg, amino acid (Table 1):1g/kg, carnitine: 68mg/kg, and CoQ10:10mg/kg, capacity: 10ml/kg) was contained as the amount specifically orally administered). After 30 minutes of oral administration, the rats were simultaneously immersed in warm water (35. + -. 1 ℃) having a water depth of 45cm and allowed to swim for 1 hour. Blood glucose values were measured by taking blood from the tail vein immediately after exercise. In addition, plasma was separated from the obtained blood, and plasma corticosterone concentration was measured. The blood glucose level was measured by a blood glucose measuring apparatus BREEZE2 (bayer chemical). In addition, corticosterone was measured by the RODENT corticosterone ELISA kit (INC.).
Results for blood glucose values and plasma corticosterone concentrations are presented as mean ± standard deviation. The mean value and standard deviation of blood glucose levels immediately after exercise are shown in table 2, and the mean value ± standard deviation of plasma corticosterone concentrations immediately after exercise are shown in table 3. The products of the present invention were confirmed to have higher anti-fatigue effects than water and the existing products.
[ Table 1]
[ Table 2]
| Water (W) | Articles of the invention | Existing articles |
| 66±3.5 | 82±4.6 | 67±5.0 |
[ Table 3]
| Water (W) | Articles of the invention | Existing articles |
| 196±6.2 | 163±4.5 | 177±8.0 |
[ example 2]
AUC and Cmax determination of plasma Glycerol concentration (animal test)
24 Wistar male rats were purchased from Japanese SLC corporation and acclimatized for 1 week. Rats were fasted for less than 18 hours from the evening of the day before the experiment. However, water is freely ingested. On the day of the test, rats were orally administered (dose: 1g/kg, volume: 10ml/kg) test substances (water, inventive product A (obtained by diluting 10 times with water an amino acid composition comprising 18:11: 1L-arginine: L-valine: L-serine in weight ratio), inventive product B (obtained by diluting 10 times with water an amino acid-containing composition comprising 15:14:1 arginine: valine in weight ratio), conventional products (obtained by diluting 1 time with water the amino acid-containing granules of Table 1), 30 minutes after oral administration of the test substances, 0.2mg/kg and 8 ml/kg. of adrenaline were administered intraperitoneally, and 8 ml/kg. were administered to simulate the lipid metabolism during exercise, which is the promotion of the decomposition of neutral fat by the secretion of adrenaline Blood was collected from the tail vein before adrenaline administration and after adrenaline administration for 15, 30, 45, 60, 75, and 90 minutes with time. Plasma was separated from the resulting blood and plasma glycerol concentrations were determined by glycerol colorimetric kit (Cayman Chemical Company). In addition, the area under the curve (AUC) and the maximum blood concentration (Cmax) of the plasma glycerol concentration were calculated. Results are expressed as mean ± standard deviation.
Mean and standard deviation of glycerol AUC are shown in table 4, mean ± standard deviation of glycerol Cmax are shown in table 5. AUC of the plasma glycerol concentration and Cmax of the plasma glycerol concentration of the inventive product a and the inventive product B showed higher values than water. The product of the present invention was confirmed to have an effect of enhancing lipid metabolism.
[ Table 4]
| Water (W) | Inventive articles A | Inventive article B | Existing articles |
| 270±58 | 673±156 | 437±47 | 732±97 |
[ Table 5]
| Water (W) | Inventive articles A | Inventive article B | Existing articles |
| 8.7±1.3 | 14±1.8 | 10±0.7 | 14±1.6 |
[ example 3]
Spontaneous motility assay (animal test)
36 SD male rats of 5 weeks old were purchased from Korea, Japan, and acclimatized and raised for 2 weeks. Rats were fasted within 18 hours from the evening of the day before the experiment. However, water is freely ingested. On the day of the test, the test substance (water, the preparation of the present invention (an amino acid-containing composition consisting of arginine: valine: serine in a weight ratio of 18:11: 1)) was orally administered to rats. After 30 minutes of oral administration, the mixture was added to warm water (35. + -. 1 ℃) having a water depth of 45cm and then allowed to swim for 1 hour. The spontaneous motility (accumulation) was measured by a rat spontaneous motility measuring apparatus for 30 minutes after the termination of the motility. The spontaneous motility after exercise was measured by using a rat motility measuring apparatus ACTIMO-10N (SHIN FACTORY).
Results are expressed as mean ± standard deviation. The mean and standard deviation of spontaneous exercise amount after exercise are shown in Table 6. It was confirmed that the spontaneous motility 30 minutes after exercise of the product of the present invention was 50% higher than that of water, and that the product had a high anti-fatigue effect.
[ Table 6]
| Water (W) | Articles of the invention |
| 261±14 | 311±20 |
[ example 4]
Test for confirming hyperfunction of anti-fatigue Effect (human body test)
The subject is a healthy male of 20-40 years old. The experimental design used a double-blind crossover test. In this test, a test food was ingested once, and a permanent exercise stress test using a bicycle dynamometer (Aerobike (registered trademark) 75XLIII (KONAMI sports and living, ltd.) was performed from 30 minutes later. The exercise load conditions employed 2 repetitions of 40 minute exercise at 3 minute rest intervals with an exercise load corresponding to 50% of VO2max of each subject. The test food used 5 capsules in which 3000mg of the product of the present invention (an amino acid-containing composition comprising arginine, valine and serine at a weight ratio of 18:11: 1) was sealed or 5 capsules in which no amino acid was sealed and the presence or absence of the amino acid-containing composition was visually indistinguishable (control product). Blood was collected at rest, before exercise load, after exercise load, 30 minutes and 60 minutes, and the cortisol concentration in blood was measured from the obtained blood.
Fig. 1 shows the average value of the amount of change in the blood cortisol concentration from before exercise load to after exercise load (15 subjects to be analyzed for efficacy). The blood cortisol concentration of the product of the present invention was found to be significantly lower than that of the control, and the product had an anti-fatigue effect.
[ example 5]
Comparative somatosensory test for tension and relaxation of muscle (human body test)
The subject is a healthy male sportsman aged 20-30 years. As a preliminary examination, a lifestyle questionnaire and physical measurements were performed, and a subject was selected and then subjected to the test. The experimental design used a double-blind crossover test. In this test, the test food was ingested once, and any exercise was performed from 30 minutes later. The test food used 5 capsules in which 3000mg of the product of the present invention (an amino acid-containing composition comprising arginine, valine and serine in a weight ratio of 18:11: 1) or 5 capsules in which conventional products (amino acid: 3000mg, carnitine: 200mg, and CoQ10:30mg in Table 1) were sealed. VAS (visual analogue score) was performed before and after the exercise.
Table 7 shows the average value and standard deviation of VAS change amounts from before the exercise load to after the exercise load was completed (9 items to be analyzed for effectiveness). The "tension and relaxation of muscles" of the product of the present invention was confirmed to be lower than those of the conventional products, and the product had an anti-fatigue effect.
[ Table 7]
| Existing articles | Articles of the invention |
| 33.6±8.8 | 25.9±6.9 |
[ example 6]
Body feeling comparison test (human body test) for fatigue
The subject is a healthy male sportsman aged 20-30 years. As a preliminary examination, a lifestyle questionnaire and physical measurements were performed, and a subject was selected and then subjected to the test. The experimental design used a double-blind crossover test. In this test, the test food was ingested once, and any exercise was performed from 30 minutes later. The test food used 5 capsules containing 1300mg of the product of the present invention (an amino acid-containing composition comprising arginine, valine and serine at a weight ratio of 18:11: 1) or 5 capsules containing 3000mg of the conventional product (amino acid in Table 1). VAS (visual analogue score) was performed before and after the exercise.
Table 8 shows the average value and standard deviation of VAS change amounts from before the exercise load to after the exercise load was completed (18 items to be analyzed for effectiveness). It was confirmed that the product of the present invention had a low "fatigue feeling" and an anti-fatigue effect, although the types and amounts of amino acids were small as compared with the conventional products.
[ Table 8]
| Existing articles | Articles of the invention |
| 14.4±4.4 | 8.8±4.2 |
[ example 7]
Storage stability of amino acid-containing composition
A capsule containing an amino acid-containing composition was prepared by filling 1800mg of L-arginine, 1100mg of L-valine and 100mg of L-serine in a cellulose white capsule No. 00, and filled in an aluminum bag container. The composition containing amino acids was not decomposed (decreased) in the capsules after being kept at room temperature for 2 weeks.
Possibility of industrial utilization
Since the prevention and reduction of fatigue during exercise, the lipid metabolism-enhancing effect, and the improvement of exercise efficiency and motivation for exercise are possible, it is possible to design a food for maintaining and improving the possibility that a person with little exercise amount will exercise habitually and the exercise efficiency of an exercise enthusiast and an athlete. In this case, since it is advantageous to extend the health life of japanese, it can contribute significantly to society by reducing medical expenses and the like.
Claims (10)
1. Use of an amino acid composition in the manufacture of an amino acid containing composition for anti-fatigue use, wherein the amino acids in the amino acid composition are arginine, valine and serine, and the weight ratio of arginine, valine and serine is 18:11: 1.
2. The use according to claim 1, wherein the composition further comprises non-amino acid ingredients as an anti-fatigue active ingredient.
3. Use of an amino acid composition in the manufacture of an anti-fatigue agent, wherein the amino acids in the amino acid composition are arginine, valine and serine, and the weight ratio of arginine, valine and serine is 18:11: 1.
4. The use as claimed in claim 3, wherein the composition further comprises non-amino acid ingredients as active ingredients of the antifatigue agent.
5. The use according to any one of claims 1 to 2, wherein the anti-fatigue amino acid-containing composition comprises 50% by weight of arginine.
6. Use according to any one of claims 3 to 4, wherein the anti-fatigue agent comprises 50% by weight of arginine.
7. The use according to any one of claims 1 to 2, wherein the anti-fatigue amino acid-containing composition contains 25% by weight of valine.
8. Use according to any one of claims 3 to 4, wherein the anti-fatigue agent contains 25% by weight of valine.
9. Use according to any one of claims 1 to 2, wherein the anti-fatigue amino acid-containing composition comprises 0.1% by weight serine.
10. Use according to any one of claims 3 to 4, wherein the antifatigue agent comprises serine in an amount of 0.1% by weight.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016-029749 | 2016-02-19 | ||
| JP2016029749 | 2016-02-19 | ||
| JP2016103402 | 2016-05-24 | ||
| JP2016-103402 | 2016-05-24 | ||
| PCT/JP2017/005825 WO2017142052A1 (en) | 2016-02-19 | 2017-02-17 | Amino acid-containing composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108697679A CN108697679A (en) | 2018-10-23 |
| CN108697679B true CN108697679B (en) | 2021-08-31 |
Family
ID=59626193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780011660.1A Active CN108697679B (en) | 2016-02-19 | 2017-02-17 | Amino acid-containing composition |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP6942113B2 (en) |
| CN (1) | CN108697679B (en) |
| HK (1) | HK1255012A1 (en) |
| WO (1) | WO2017142052A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019024389A (en) * | 2017-07-28 | 2019-02-21 | 株式会社明治 | Amino acid composition for improved muscle strength |
| CN111296843A (en) * | 2020-03-03 | 2020-06-19 | 上海泓商生物科技有限公司 | Anti-fatigue and sports probiotics |
| KR102235563B1 (en) * | 2020-08-26 | 2021-04-02 | (주)이삼오구 | Composition for fatigue recovery and sexual function improvement containing high content of arginine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200603790A (en) * | 2004-04-19 | 2006-02-01 | Kirin Brewery | Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis |
| JP4854199B2 (en) * | 2005-01-17 | 2012-01-18 | 大関株式会社 | Functional material obtained by re-fermenting liquefied sake lees |
| JP2007161675A (en) * | 2005-12-16 | 2007-06-28 | Taisho Pharmaceut Co Ltd | Fatigue-improving internal medicine |
| JP5812565B2 (en) * | 2007-02-28 | 2015-11-17 | 株式会社明治 | Amino acid composition |
| JP2016102064A (en) * | 2013-08-14 | 2016-06-02 | 株式会社明治 | Lipid metabolism accelerating agent |
| JP6378513B2 (en) * | 2014-03-24 | 2018-08-22 | アサヒ飲料株式会社 | Hesperidin-containing beverage, bitterness improving agent, and bitterness improving method |
-
2017
- 2017-02-17 JP JP2018500217A patent/JP6942113B2/en active Active
- 2017-02-17 CN CN201780011660.1A patent/CN108697679B/en active Active
- 2017-02-17 WO PCT/JP2017/005825 patent/WO2017142052A1/en active Application Filing
-
2018
- 2018-11-06 HK HK18114133.9A patent/HK1255012A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2017142052A1 (en) | 2018-12-13 |
| JP6942113B2 (en) | 2021-09-29 |
| WO2017142052A1 (en) | 2017-08-24 |
| CN108697679A (en) | 2018-10-23 |
| HK1255012A1 (en) | 2019-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5507802B2 (en) | Muscle aging inhibitor | |
| CN103501632A (en) | Bite-size nutritional products having a filling and methods for using same | |
| JP2014513527A (en) | Nutritional composition for improving performance and method for producing and using the same | |
| NO333013B1 (en) | Composition comprising bioactive amino acids or derivatives thereof and marine oil in a stable oil-in-water emulsion, and process for preparing said composition. | |
| US20150366257A1 (en) | Nutritionally complete composition for calorie-balanced diet | |
| US20160367529A1 (en) | Debility preventative | |
| CN108697679B (en) | Amino acid-containing composition | |
| TWI773739B (en) | A composition for promoting the increase in the amount of BDNF in the body | |
| JP2006273850A (en) | Suppression composition for lactic acid value elevation in blood, and food and drink comprising same | |
| MX2014011296A (en) | Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance. | |
| US20070248648A1 (en) | High protein, fatigue reducing powder | |
| WO2017026429A1 (en) | Muscle synthesis promoting agent | |
| US20120282232A1 (en) | Nutrient Hydration Bar | |
| WO2015137387A1 (en) | Muscle enhancing drug | |
| Jusoh et al. | Evaluation of nutritive values and consumer acceptance of sweet corn (Zea mays) juice as a recovery beverage for exercising people | |
| US20190070139A1 (en) | Agent for improving physical fitness | |
| WO2020027012A1 (en) | Soy protein beverage | |
| JP6646369B2 (en) | Anti-fatigue agent | |
| JP7462338B2 (en) | Anti-fatigue | |
| JP2015529470A (en) | Composition containing β-hydroxy-β-methylbutyric acid (METHYLBUTRYICACID) and use thereof | |
| TW201909891A (en) | Amino acid composition for promoting noradrenaline secretion | |
| TW201909759A (en) | Amino acid composition for promoting muscle strength | |
| JP2020043825A (en) | Cacao bean workpiece-containing beverage | |
| JP6829487B2 (en) | Anti-fatigue | |
| CN114364267B (en) | Novel flavor composition, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1255012 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |